The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab
Abstract
Objective: Infliximab, an anti–tumor necrosis factor α (anti‐TNFα) antibody, is effective in the treatment of several immunoinflammatory diseases. However, many patients experience primary or secondary response failure, suggesting that individualization of treatment regimens may be beneficial. This study was undertaken to investigate whether serologic monitoring of infliximab bioavailability and immunogenicity in individual patients would be useful in optimizing treatment regimens to improve efficacy and tolerability. Methods: To avoid the use of solid‐phase assays, two radioimmunoassays were developed: one for measurement of levels of anti‐infliximab antibody, and a functional one for measurement of TNFα binding due to infliximab. Sera from 106 randomly selected rheumatoid arthritis patients were tested within 6 months of therapy initiation, and associations between findings of serum assays and disease activity, infusion reactions, and treatment failure occurring within 18 months were assessed. Results: Trough serum infliximab levels after the first 2 intravenous infusions of infliximab at 3 mg/kg varied considerably between patients (range 0–22 μg/ml). At this stage, only 13% of the patients were anti‐infliximab antibody positive. With subsequent infusions, the frequency of antibody positivity rose to 30% and 44% (at 3 months and 6 months, respectively), accompanied by diminished trough levels of infliximab. Indeed, low infliximab levels at 1.5 months predicted antibody development and later treatment failure. There were highly significant correlations between high levels of antibodies and later dose increases, side effects, and cessation of therapy. High baseline disease activity, judged by C‐reactive protein level and Disease Activity Score, was associated with low levels of infliximab at the early stage of treatment and later development of anti‐infliximab antibodies. Cotreatment with methotrexate resulted in slightly reduced antibody levels after 6 months; other disease‐modifying antirheumatic drugs and prednisolone had no effect. Conclusion: Development of anti‐infliximab antibodies, heralded by low preinfusion serum infliximab levels, is associated with increased risk of infusion reaction and treatment failure. Early monitoring may help optimize dosing regimens for individual patients, diminish side effects, and prevent prolonged use of inadequate infliximab therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., MACFARLANE, J. D., Antoni, C., Leeb, B. F., Elliott, M. J., Woody, J. N., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w · Cited by 1,623
Wolbink, G. J., Vis, M., Lems, W., Voskuyl, A. E., De Groot, E., Nurmohamed, M. T., Stapel, S., Tak, P. P., Aarden, L., & Dijkmans, B. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21671 · Cited by 471
St.Clair, E. W., Wagner, C. L., Fasanmade, A. A., Wang, B., Schaible, T., Kavanaugh, A., & Keystone, E. C. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10302 · Cited by 417
Kapetanovic, M. C., Saxne, T., Sjöholm, A., Truedsson, L., Jönsson, G., & Geborek, P. (2006) · Rheumatology · doi:10.1093/rheumatology/kei193 · Cited by 319
Self-citationGomez-Reino, J. J., Carmona, L., & the BIOBADASER Group (2006) · Arthritis Research & Therapy · doi:10.1186/ar1881 · Cited by 289
Geborek, P., Crnkic, M., Petersson, I. F., & Saxne, T. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.9.793 · Cited by 253
Self-citationWolbink, G. J., Voskuyl, A. E., Lems, W. F., de Groot, E., Nurmohamed, M. T., Tak, P. P., Dijkmans, B. A. C., & Aarden, L. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.030452 · Cited by 215
Gottlieb, A. B., Masuda, S., Ramamurthi, R., Abdulghani, A. A., Romano, P., Chaudhari, U., Dooley, L. T., Fasanmade, A. A., & Wagner, C. L. (2003) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2003.10 · Cited by 153
Monoclonal antibodies, immunogenicity, and associated infusion reactions.
Cheifetz, A. S., & Mayer, L. (2005) · PubMed · Cited by 152
Miele, E., Markowitz, J. E., Mamula, P., & Baldassano, R. N. (2004) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-200405000-00008 · Cited by 125
Hennig, C., Rink, L., Fagin, U., Jabs, W. J., & Kirchner, H. (2000) · Journal of Immunological Methods · doi:10.1016/s0022-1759(99)00206-9 · Cited by 117
Infliximab: An Updated Review of its Use in Crohn??s Disease and Rheumatoid Arthritis
Keating, G. M., & Perry, C. M. (2002) · BioDrugs · doi:10.2165/00063030-200216020-00005 · Cited by 102
Anti-TNF therapy: Where have we got to in 2005?
Feldmann, M., Brennan, F. M., Foxwell, B. M. J., Taylor, P. C., Williams, R. O., & Maini, R. N. (2005) · Journal of Autoimmunity · doi:10.1016/j.jaut.2005.09.006 · Cited by 92
Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade.
Wagner, C. L., Schantz, A., Barnathan, E. S., Olson, A., Mascelli, M. A., Ford, J., Damaraju, L. V., Schaible, T., Maini, R. N., & Tcheng, J. E. (2003) · PubMed · Cited by 85
Drugs that block tumour necrosis factor: Experience in patients with rheumatoid arthritis
Moreland, L. W. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422001-00005 · Cited by 62
Anti-IFN BAb and NAb antibodies
Bendtzen, K. (2003) · Neurology · doi:10.1212/01.wnl.0000092357.07278.09 · Cited by 49
Self-citationOptimizing anti-tumor necrosis factor strategies in inflammatory bowel disease
Sandborn, W. J. (2003) · Current Gastroenterology Reports · doi:10.1007/s11894-003-0040-8 · Cited by 43
Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors
Anderson, P., Louie, J. S., Lau, A., & Broder, M. S. (2005) · Current Rheumatology Reports · doi:10.1007/s11926-005-0002-2 · Cited by 18
Cited by
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Bartelds, G. M. (2011) · JAMA · doi:10.1001/jama.2011.406 · Cited by 782
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725
Yoo, D. H., Hrycaj, P., Miranda, P., Ramiterre, E., Piotrowski, M., Shevchuk, S., Kovalenko, V., Prodanovic, N., Abello-Banfi, M., Gutierrez-Ureña, S., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-203090 · Cited by 654
Ben-Horin, S., & Chowers, Y. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04612.x · Cited by 620
Metadata
- Authors
- Bendtzen, K., Geborek, P., Svenson, M., Larsson, L., Kapetanovic, M. C., & Saxne, T.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2006-11-28
- Volume
- 54
- Issue
- 12
- Pages
- 3782-3789
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2166771071
- Cited by
- 384
- References
- 23
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.